21 CFR 882.5955 — Temporary Coil Embolization Assist Device
Neurology (NE) · Part 882 Subpart F—Neurological Therapeutic Devices · § 882.5955
Identification
A temporary coil embolization assist device is a prescription device intended for temporary use in the neurovasculature to mechanically assist in the embolization of intracranial aneurysms with embolic coils. The device is delivered into the neurovasculature with an endovascular approach. This device is not intended to be permanently implanted and is removed from the body when the procedure is completed.
Classification Rationale
Class II (special controls). The special controls for this device are:
Product Codes
| Product Code | Device Name | Class | Devices | Attributes |
|---|---|---|---|---|
| PUU | Temporary Coil Embolization Assist Device | 2 | 1 |
Special Controls
PUU — Temporary Coil Embolization Assist Device
*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing of the device must demonstrate the device performs as intended for temporary use as an endovascular device to assist in the coil embolization of intracranial aneurysms and must evaluate all adverse events, including tissue or vessel damage that could lead to dissection, perforation, hemorrhage, or vasospasm, thrombo-embolic events, and coil entanglement. (2) The patient-contacting components of the device must be demonstrated to be biocompatible. (3) Non-clinical performance testing must demonstrate the device performs as intended under anticipated conditions of use, including: (i) Mechanical testing to demonstrate the device can withstand anticipated tensile, torsional, compressive, and tip deflection forces; (ii) Mechanical testing to evaluate the radial forces exerted by the device; (iii) Simulated use testing to demonstrate the device can be delivered to the target location in the neurovasculature and is compatible with embolic coils; (iv) Dimensional verification testing; (v) Radiopacity testing; and (vi) Performance testing to evaluate the coating integrity and particulates under simulated use conditions. (4) Animal testing under anticipated use conditions must evaluate all adverse events, including damage to vessels or tissues. (5) Performance data must support the sterility and pyrogenicity of the device. (6) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the labeled shelf life. (7) The labeling must include: (i) Instructions for use; (ii) A detailed summary of the device technical parameters, including compatible delivery catheter dimensions and device sizing information; (iii) A summary of the clinical testing results, including a detailed summary of the device- and procedure-related complications and adverse events; and (iv) A shelf life.
eCFR
PUU — Temporary Coil Embolization Assist Device
(1) Clinical performance testing of the device must demonstrate the device performs as intended for temporary use as an endovascular device to assist in the coil embolization of intracranial aneurysms and must evaluate all adverse events, including tissue or vessel damage that could lead to dissection, perforation, hemorrhage, or vasospasm, thrombo-embolic events, and coil entanglement. (2) The patient-contacting components of the device must be demonstrated to be biocompatible. (3) Non-clinical performance testing must demonstrate the device performs as intended under anticipated conditions of use, including: (i) Mechanical testing to demonstrate the device can withstand anticipated tensile, torsional, compressive, and tip deflection forces; (ii) Mechanical testing to evaluate the radial forces exerted by the device; (iii) Simulated use testing to demonstrate the device can be delivered to the target location in the neurovasculature and is compatible with embolic coils; (iv) Dimensional verification testing; (v) Radiopacity testing; and (vi) Performance testing to evaluate the coating integrity and particulates under simulated use conditions. (4) Animal testing under anticipated use conditions must evaluate all adverse events, including damage to vessels or tissues. (5) Performance data must support the sterility and pyrogenicity of the device. (6) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the labeled shelf life. (7) The labeling must include: (i) Instructions for use; (ii) A detailed summary of the device technical parameters, including compatible delivery catheter dimensions and device sizing information; (iii) A summary of the clinical testing results, including a detailed summary of the device- and procedure-related complications and adverse events; and (iv) A shelf life.
Ecfr Llm
